Overview Key strengths Key risks Good expected top-line growth across all major segments. Increasingly competing against larger, broader rivals, such as Medtronic and Abbott Laboratories. Growth across a broad portfolio of young products highlights management?s successful R&D and product acquisition strategy. Likely to remain acquisitive but maintain relatively conservative financial policies; should stay comfortably under our downside adjusted leverage trigger. Boston Scientific is seeing strong growth across newer products and categories. The company continues to benefit from strong organic growth from its portfolio of newer products, such as WATCHMAN (grew 23% in third-quarter 2023), its pulse field ablation system FARAPULSE, transcatheter aortic valve replacement TAVR, and aortic valve system Accurate neo2. We continue to expect total revenue to increase roughly
